Mammary Carcinoma

Breast cancer is the second most common cancer among women worldwide. Hypoxia inducible factor-¿ (HIF-¿) is a heterodimer, which can acts as a key regulator to decrease the oxygen level in the cellular activity. Therefore, HIF-¿ playing a vital role in the tumor progression. Here, we identified a novel peptide using insilco analysis. The present study was carried out of different peptides which were screened with insilco analysis. The identified peptide HIF9 binding to the p-aminosalicylic acid (PAS-B) domain and hinders the dimerization and transcription activity. Further, the quantification method for peptide HIF9 by HPLC was developed and validated which is not available. Additionally, the nano formulations were made with varying peptide and chitosan. The formulation was tested for surface morphology, Plasma stability, Geno toxicity, Hemo compatibility, and Embryo toxicity. The apoptotic effectof Peptide Chitosan Nanoparticles (PCN-M04) was assessed in the MCF-7 breast cancer cells which confirmed the safety and efficiency. Hence, the PCN-M04 therapy for mammary carcinoma was further confirmed with in vivo evaluation using DMBA induced by the mammary carcinoma rat model.